RCM TECHNOLOGIES INC
For the period ended Dec 30, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. OTHER INFORMATION
Rule 10b5-1 Trading Plans
Pursuant to Item408(a) of Regulation S-K, the Company’s directors and officers (as defined in Rule16a-1(f) under the Exchange Act) adopted, terminated, or modified a “Rule10b5-1 trading arrangement” in the fiscal year ended* December 30, 2023*as follows:
| Name · Position · Action · Adoption Date · Expiration Date · Aggregate Numbers of Common Stock to be Purchased/Sold | ||||||
|---|---|---|---|---|---|---|
| Bradley S. Vizi | Executive Chairman & President | Adopted | December 7, 2023 | March 7, 2026 | 650,000 | (1) |
| Michael Saks | Division President, Health Care Services | Adopted | December 5, 2023 | December 1, 2024 | 18,000 | |
(1) The aggregate number of shares that can be sold under the plan is allocated into a series of tranches that would be sold at laddered prices as outlined in the plan.
Other than as disclosed above,no other officer or director of the Company adopted, terminated, or modified a “Rule10b5-1 trading arrangement” or “non-Rule10b5-1 trading arrangement,” as each term is defined in Item408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.